证券代码：688161 证券简称：威高骨科 公告编号：2026-005 山东威高骨科材料股份有限公司2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载山东威高骨科材料股份有限公司（以下简称"公司"）2025年度主要财务数据为初步核算数 据，未经会计师事务所审计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度的定期报告为 准。 3.数据若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 报告期内，公司营业收入153,919.23万元，较上年同期增长5.95%；实现归属于母公司所有者的净利润 26,663.92万元，较上年同期增长19.17 %；实现归属于母公司所有者的扣除非经常性损益的净利润 25,218.28万元，同比增长19.59%。报告期内，公司实施2 ...

公告称，报告期内，骨科带量采购总体执行平稳，国产头部品牌市场份额持续提升。 销售方面，公司 积极进行销售模式和销售组织结构的调整，打造以专业科室为核心维度的事业部利润中心制，推动营销 架构优化升级，激发销售组织活力;进一步细分产品线，通过销售事业部细分管理，提高销售队伍的专 业能力和聚焦度，更精准的进行临床服务和市场学术引领;通过聚焦关键术式的多产线协同销售，核心 重点医院业务增量明显，同时加大下沉市场的开发以及创新产品的推广，整体手术量持续增长，带来收 入和销量的持续增长。 威高股份(01066)发布发布山东威高骨科材料股份有限公司(688161.SH)2025年度业绩快报，该公司取得 营业收入15.39亿元(人民币，下同)，同比增长5.95%;归属于母公司所有者的净利润2.67亿元，同比增长 19.17%;基本每股收益0.67元。 来源：智通财经网 ...

威高股份(01066)发布发布山东威高骨科材料股份有限公司(688161.SH)2025年度业绩快报，该公司取得 营业收入15.39亿元(人民币，下同)，同比增长5.95%;归属于母公司所有者的净利润2.67亿元，同比增长 19.17%;基本每股收益0.67元。 公告称，报告期内，骨科带量采购总体执行平稳，国产头部品牌市场份额持续提升。销售方面，公司积 极进行销售模式和销售组织结构的调整，打造以专业科室为核心维度的事业部利润中心制，推动营销架 构优化升级，激发销售组织活力;进一步细分产品线，通过销售事业部细分管理，提高销售队伍的专业 能力和聚焦度，更精准的进行临床服务和市场学术引领;通过聚焦关键术式的多产线协同销售，核心重 点医院业务增量明显，同时加大下沉市场的开发以及创新产品的推广，整体手术量持续增长，带来收入 和销量的持续增长。 ...

智通财经APP讯，威高股份(01066)发布发布山东威高骨科材料股份有限公司(688161.SH)2025年度业绩 快报，该公司取得营业收入15.39亿元(人民币，下同)，同比增长5.95%;归属于母公司所有者的净利润 2.67亿元，同比增长19.17%;基本每股收益0.67元。 公告称，报告期内，骨科带量采购总体执行平稳，国产头部品牌市场份额持续提升。 销售方面，公司 积极进行销售模式和销售组织结构的调整，打造以专业科室为核心维度的事业部利润中心制，推动营销 架构优化升级，激发销售组织活力;进一步细分产品线，通过销售事业部细分管理，提高销售队伍的专 业能力和聚焦度，更精准的进行临床服务和市场学术引领;通过聚焦关键术式的多产线协同销售，核心 重点医院业务增量明显，同时加大下沉市场的开发以及创新产品的推广，整体手术量持续增长，带来收 入和销量的持续增长。 ...

Core Viewpoint - The announcement details the implementation of the 2025 semi-annual profit distribution plan by Shandong Weigao Orthopedic Materials Co., Ltd, which includes a cash dividend of 0.10 yuan per share [1][4]. Distribution Plan - The distribution year is set for the 2025 semi-annual period [2]. - Eligible recipients include all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [2]. - The company has authorized the board to determine the specific distribution plan based on the conditions and limits approved at the 2024 annual shareholders' meeting [3]. Financial Details - The net profit attributable to shareholders for the first half of 2025 is reported at 141,957,058.61 yuan, with retained earnings amounting to 2,190,103,574.82 yuan [3]. - The cash flow from operating activities for the first half of 2025 is 186,207,847.40 yuan, indicating sufficient funds for normal operations and sustainable development [3]. - The total share capital is 400,000,000 shares, with 2,713,876 shares in the company's repurchase account excluded from the distribution, resulting in a distribution base of 397,286,124 shares [4]. Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan for every 10 shares held, totaling 39,728,612.40 yuan, which represents 27.99% of the net profit attributable to shareholders for the first half of 2025 [4]. - The distribution will not involve capital reserve conversion to share capital or stock dividends [4]. Taxation Information - For individual shareholders holding unrestricted shares, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for less than one month [9][10]. - For foreign institutional investors, a 10% withholding tax applies to dividends received [11]. - The company will not withhold taxes for other institutional investors, who are responsible for their own tax declarations [12]. Implementation Method - The dividends will be distributed through China Securities Depository and Clearing Corporation Limited, with specific arrangements for shareholders who have designated trading [5][6]. - Shareholders who have not designated trading will have their dividends held until they complete the necessary procedures [5]. Contact Information - For inquiries regarding the distribution, shareholders can contact the company's securities affairs department at 0631-5788909 [13].

Core Insights - The article discusses the development and branding strategies of Weigao Group in the medical and healthcare industry, emphasizing their commitment to quality management and innovation Group 1: Brand and Quality Management - Weigao Group has been recognized with a nomination for the China Quality Award, establishing a diversified brand system centered around "WEGO" [1] - The company implements a quality philosophy termed "10000-1=0," which signifies that even a minor defect can lead to total failure, reinforcing the importance of quality as the brand's lifeline [2] - Weigao has established a comprehensive traceability quality control system from raw material procurement to finished products, aiming for "zero defects" in product reliability [2] Group 2: Innovation and Market Leadership - Innovation is a core driver for Weigao, which holds over 2100 patents and has established 15 national and provincial innovation platforms [3] - The company has successfully broken monopolies in key areas such as medical materials and devices, transitioning from import substitution to international leadership [3] - Collaborations with institutions like the Chinese Academy of Sciences have enabled Weigao to develop domestic alternatives to imported materials, fostering a new growth dynamic in the medical device sector [3] Group 3: Cultural Integration and Brand Identity - Weigao emphasizes the integration of internal culture and external values, promoting a core value system of "conscience, sincerity, and loyalty" [4] - The company's mission is deeply embedded in its brand culture, encouraging over 30,000 employees to embody and promote the brand's values [4] - This cultural drive transforms employee pride into a pursuit of product excellence, enhancing customer trust and societal expectations of the brand [4]

Group 1 - The core investment of 4.5 billion yuan in the establishment of Mindray Medical's second global headquarters in Wuhan aims to accelerate the development of a biomedicine and medical device industry cluster in the region [1][2] - The Wuhan base covers an area of 110 acres and includes a research and development base and a production base, featuring approximately 13,000 square meters of specialized laboratory space and over 90 laboratories [1] - The production base will focus on high-end manufacturing of orthopedic materials, minimally invasive surgical instruments, and biological raw materials, leveraging digital construction [1] Group 2 - Mindray Medical's senior vice president stated that the Wuhan base will serve as a "cultivation dish" for the company's second growth curve, encompassing the entire value chain from R&D to manufacturing and customer training [2] - The base plans to recruit 2,000 employees within five years, with 60% of them being R&D talents, supported by local talent policies to create a "Silicon Valley-like" ecosystem [2] - The establishment of the base is expected to attract over 100 supporting enterprises, further enhancing the high-end medical equipment industry cluster in Wuhan [2] Group 3 - Mindray Medical is recognized as China's largest and a global leader in the medical device sector, with products spanning life information and support, in vitro diagnostics, and medical imaging, distributed in over 190 countries and regions [2] - The registered capital of Mindray's wholly-owned subsidiary in Wuhan increased from 500 million yuan to 2 billion yuan in June, marking a 300% increase [2] - The president of Mindray emphasized that Wuhan is not only a crucial talent supply base but also a core component of the company's long-term strategy [2]

创业板投资风险提示 融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高 等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险 及本公司所披露的风险因素，审慎作出投资决定。 国科恒泰（北京）医疗科技股份有限公司 （北京市北京经济技术开发区经海四路 25 号 6 号楼 5 层 501C 室） 首次公开发行股票并在创业板上市 招股意向书 保荐人（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业 招股意向书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股意向书 ...

本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业 融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高 等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险 及本公司所披露的风险因素，审慎作出投资决定。 国科恒泰（北京）医疗科技股份有限公司 （北京市北京经济技术开发区经海四路 25 号 6 号楼 5 层 501C 室） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 声明：本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程 序。本招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者 应当以正式公告的招股说明书作为投资决定的依据。 保荐机构（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 创业板投资风险提示 招股说明书（注册稿） 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票 ...